Investor Presentaiton slide image

Investor Presentaiton

Mirren Revenue FY18 ZAR 152m 1√2.9% vs. LY Coryx: Cough & Cold Broncol: Cough & Cold ↑15% Tab & syrup market growth (Cough & Cold) "CORYX Cold &fu relief 2 Efervescent tablets 4 day bang 190% Syrup market growth with no BRONCOL Cipla SA signs a definitive agreement to acquire 100% stake in Mirren (Pty) Ltd. Deal is subject to SA Competition Commission Approval Key Transaction Financials OTC Growth in SA 11% ~300bps higher than overall market Cipla Valuation Metrics ZAR 450m 3x FY18 Sales Ultimag: Mag & Zinc Supplement Tensopyn: Pain Mgmt. 150% BRONCOL codeine (Cough & Cold) Tab & syrup market growth (Pain Mgmt) Local manufacturing facility for liquids, OSD & Effervescent Tab & syrup market growth (Mag & Zinc Supplement) TENSOPYN For TENSION PAN TENSOPYN 130% "ULTIMAG ZINC Synergies & Capabilities • Play in the ZAR11Bn OTC market Cipla OTC Accelerate OTC business to reach ZAR 1Bn 18% of 14% Expand presence in Pain, Cough & Cold therapeutic area Access to local liquid manufacturing facility Cipla overall YOY business Targeted Market ZAR3bn Investor Presentation: QIFY19 Cipla + Mirren 22%+ of Cipla overall business Targeted Market ZAR14bn
View entire presentation